🟢 Crispr Therapeutics is trading 4.02% up today ahead of scheduled Morgan Stanley presentation

Crispr Therapeutics is trading 4.02% up at $53.80, possibly supported by investor interest ahead of its scheduled Morgan Stanley presentation.

• The stock is rebounding from the September 11 close of $51.72 after several consecutive declines.
• No definitive September 14, 2026 company-specific catalyst directly explaining the move was identified.
• Management is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference at 1:05 p.m. EST, but the presentation had not occurred by 12:22 p.m.